Lewin SRAttoye TBansbach CDoehle BDubé KDybul MSenGupta DJiang AJohnston RLamplough RMcCune JMNabel GJNdung'u TPottage JRipin DRooney JFSikazwe INsubuga MWarren MDeeks SG2025-05-232021-Jan10.1016/S2352-3018(20)30234-4https://pubs.cidrz.org/handle/123456789/10385Developing a cure for HIV is a global priority. Target product profiles are a tool commonly used throughout the drug development process to align interested parties around a clear set of goals or requirements for a potential product. Three distinct therapeutic modalities (combination therapies, ex-vivo gene therapy, and in-vivo gene therapy) for a target product profile for an HIV cure were identified. Using a process of expert face-to-face consultation and an online Delphi consultation, we found a high degree of agreement regarding the criteria for the optimum target product profile. Although the minimum attributes for a cure were debated, the broad consensus was that an acceptable cure need not be as safe and effective as optimally delivered antiretroviral therapy. An intervention that successfully cured a reasonable fraction of adults would be sufficient to advance to the clinic. These target product profiles will require further discussion and ongoing revisions as the field matures.